Pfizer-BioNTech COVID-19 vaccine trial

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:clinical_trial
gptkbp:adverseEvents	fever fatigue headache joint pain muscle pain chills pain at injection site mild to moderate
gptkbp:ageRange	16 years and older
gptkbp:clinicalTrials.gov_Identifier	gptkb:NCT04368728
gptkbp:doseInterval	21 days
gptkbp:doubleBlind	true
gptkbp:effect	about 95%
gptkbp:endPoint	symptomatic COVID-19 infection
gptkbp:location	gptkb:Argentina gptkb:Brazil gptkb:Germany gptkb:South_Africa gptkb:Turkey gptkb:United_States
gptkbp:numberOfDoses	2
gptkbp:participants	over 43,000
gptkbp:period	Phase 1 Phase 2 Phase 3
gptkbp:placeboControlled	true
gptkbp:publicationDate	December 2020
gptkbp:publishedIn	gptkb:The_New_England_Journal_of_Medicine
gptkbp:randomized	true
gptkbp:regulatorySubmission	gptkb:FDA gptkb:EMA gptkb:MHRA
gptkbp:result	prevention of COVID-19 vaccine authorized for emergency use
gptkbp:sponsor	gptkb:Pfizer gptkb:BioNTech
gptkbp:startDate	2020
gptkbp:studiedBy	gptkb:BNT162b2
gptkbp:vaccineType	gptkb:vaccine
gptkbp:bfsParent	gptkb:Ventavia_Research_Group
gptkbp:bfsLayer	7
https://www.w3.org/2000/01/rdf-schema#label	Pfizer-BioNTech COVID-19 vaccine trial